Paratek Pharmaceuticals Stock Current Ratio
Paratek Pharmaceuticals fundamentals help investors to digest information that contributes to Paratek Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Paratek Stock. The fundamental analysis module provides a way to measure Paratek Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Paratek Pharmaceuticals stock.
Paratek |
Paratek Pharmaceuticals Company Current Ratio Analysis
Paratek Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Paratek Pharmaceuticals Current Ratio | 3.11 X |
Most of Paratek Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paratek Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Paratek Pharmaceuticals has a Current Ratio of 3.11 times. This is 6.87% higher than that of the Pharmaceuticals sector and 55.57% lower than that of the Health Care industry. The current ratio for all United States stocks is 43.98% lower than that of the firm.
Paratek Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paratek Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics of similar companies.Paratek Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Paratek Fundamentals
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X | |||
| Revenue | 150.79 M | |||
| Gross Profit | 99.39 M | |||
| EBITDA | (44.9 M) | |||
| Net Income | (63.57 M) | |||
| Cash And Equivalents | 57.01 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 258.41 M | |||
| Debt To Equity | 3.20 % | |||
| Current Ratio | 3.11 X | |||
| Book Value Per Share | (3.52) X | |||
| Cash Flow From Operations | (66.14 M) | |||
| Short Ratio | 6.74 X | |||
| Earnings Per Share | (1.11) X | |||
| Price To Earnings To Growth | (0.02) X | |||
| Target Price | 3.1 | |||
| Number Of Employees | 268 | |||
| Beta | 1.7 | |||
| Market Capitalization | 127.83 M | |||
| Total Asset | 172.54 M | |||
| Retained Earnings | (930.45 M) | |||
| Working Capital | 99.45 M | |||
| Current Asset | 127.46 M | |||
| Current Liabilities | 21.75 M | |||
| Z Score | -6.55 | |||
| Net Asset | 172.54 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |